Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.45 |
| ▸ | LATS1 | O95835 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13987470 | 0.93 | AURKA (0.42) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL4776266 | 0.92 | AURKA (0.46) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987796 | 0.92 | CTSK (0.42) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987466 | 0.90 | AURKA (0.42) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987247 | 0.88 | CTSS (0.44) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL4779755 | 0.88 | AURKA (0.45) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987250 | 0.88 | CTSS (0.45) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987251 | 0.87 | CTSS (0.49) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL13987264 | 0.84 | AURKA (0.45) | CTSKCTSSAURKABMPR1BPLK4 | |
| SCHEMBL4779793 | 0.83 | AURKA (0.52) | AURKABMPR1BPLK4CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1585749-B1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1947102-A1 | Compositions comprising diazepinoindole derivatives as kinase inhibitors | Pfizer, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-6967198-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS INC. (US) | 2005-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | CTSK 365/4885CTSS 1040/4885AURKA 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.